SunEdison, Inc. (NYSE:SUNE), won an order to install 17.7 megawatts of panels for public agencies at more than 30 sites in California. Construction on the mix of rooftop, canopy and ground-mounted systems will begin by year-end and be complete by the end of 2015, St. Peters, Missouri-based SunEdison said in a statement. SunEdison, Inc. (NYSE:SUNE) belongs to Technology sector. Its net profit margin is -44.80% and weekly performance is 20.65%. On last trading day company shares ended up $18.23. SunEdison, Inc. (NYSE:SUNE) distance from 50-day simple moving average (SMA50) is -8.39%.

On Oct. 14, GW Pharmaceuticals plc (NASDAQ:GWPH) announced new physician reports of efficacy and safety associated with the Epidiolex® “expanded access” studies to be presented today at the Company’s R&D Day event in New York City. GW Pharmaceuticals plc (NASDAQ:GWPH) shares moved down -1.83% in last trading session and ended the day at $71.70. GWPH Gross Margin is 94.50% and its return on assets is -21.70%. GW Pharmaceuticals plc (NASDAQ:GWPH) quarterly performance is -17.56%.

On October 16, Data Link Solutions (DLS), a joint venture between Rockwell Collins Inc. (NYSE:COL) and BAE Systems, has added the TacNet? Tactical Radio (TTR) to the Link 16 product line offered to its global military aircraft customers. The move expands the Link 16 product capability to include vital Link 16 situational awareness communication to the smallest, space-constrained platforms that previously had no such capability. On 22 October, Rockwell Collins Inc. (NYSE:COL) shares moved down -1.00% and was closed at $77.37. COL EPS growth in last 5 year was 1.90%. Rockwell Collins Inc. (NYSE:COL) year to date (YTD) performance is 5.48%.

Leading Brands Inc. (NASDAQ:LBIX) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B-. Leading Brands Inc. (NASDAQ:LBIX) ended the last trading day at $3.97. Company weekly volatility is calculated as 2.19% and price to cash ratio as 6.84. Leading Brands Inc. (NASDAQ:LBIX) showed a weekly performance of 2.85%.

On Oct 13, Aratana Therapeutics, Inc. (NASDAQ:PETX) has finalized a global licensing agreement with U.K.-based Atopix Therapeutics Ltd. to develop and commercialize a drug for dogs to treat atopic dermatitis, also known as eczema. Aratana Therapeutics, Inc. (NASDAQ:PETX) shares moved down -4.67% in last trading session and ended the day at $10.21. PETX Gross Margin is 83.30% and its return on assets is -11.60%. Aratana Therapeutics, Inc. (NASDAQ:PETX) quarterly performance is -18.65%.